Biogen Soars 46% on Alzheimer’s Drug Trial. Mizuho Says the Stock Is a Buy. | Barron’s
shares were soaring Wednesday after the biopharmaceutical company said that its experimental Alzheimer’s drug with Japan-based partner
showed promising results.
Guggenheim Securities analyst Yatin Suneja called the data “a new dawn for Alzheimer’s treatment.”
to continue reading